Last reviewed · How we verify
Pheochromocytoma — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Demser | metirosine | Aton Pharma Vpna | Catecholamine Synthesis Inhibitor [EPC] | Tyrosine 3-monooxygenase | 1979-01-01 | |
| Azedra | Azedra | David Bushnell | Sodium-dependent noradrenaline transporter |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Aton Pharma Vpna · 1 drug in Pheochromocytoma
- David Bushnell · 1 drug in Pheochromocytoma
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Pheochromocytoma:
- Pheochromocytoma treatment updates — RSS
- Pheochromocytoma treatment updates — Atom
- Pheochromocytoma treatment updates — JSON
Cite this brief
Drug Landscape (2026). Pheochromocytoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/pheochromocytoma. Accessed 2026-06-10.
Related
- Pheochromocytoma full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing